The NPTX1 Knockout Raji Polyclonal Cells represent a precisely engineered CRISPR/Cas9-mediated loss-of-function model targeting the NPTX1 gene in a lymphoblastoid background. Supplied as a polyclonal population, this product consists of a heterogeneous pool of Raji cells carrying diverse gene-disruption events, enabling robust assessment of NPTX1-dependent phenotypes without clonal bias. The knockout strategy utilizes CRISPR/Cas9 ribonucleoprotein delivery to generate targeted disruptions within NPTX1, resulting in abrogation of protein expression. This format is particularly suited for studying tumor suppressor function, apoptotic signaling, and calcium-mediated pathways in B-cell malignancies, providing a versatile tool for functional genomics and drug discovery applications.
The parental Raji cell line is an Epstein-Barr virus (EBV)-positive B lymphoblastoid line originally derived from a patient with Burkitt lymphoma. It grows in suspension and serves as a well-characterized model for studying B-lymphocyte biology, lymphomagenesis, and viral transformation. Raji cells retain key features of germinal center B cells and are widely employed to investigate oncogenic signaling, DNA damage responses, and immune evasion mechanisms. Their EBV-positive status adds relevance for exploring virus?Chost interactions in B-cell lymphomas, making them an ideal host for NPTX1 knockout studies.
NPTX1 encodes neuronal pentraxin 1, a member of the pentraxin family with established roles in synaptic plasticity and AMPA receptor trafficking in neuronal systems. In B cells, NPTX1 acts as a putative tumor suppressor, transactivated by TP53 (p53) downstream of genotoxic stress and calcium influx. It promotes apoptosis through modulation of the BAX/BCL-2 balance, leading to cytochrome c release and caspase-3 activation. NPTX1 interacts with NPTXR, AMPA receptor subunits (GRIA1, GRIA2), and SNARE complex proteins, though in lymphocytes its pro-apoptotic function appears to dominate. Additional regulatory inputs include CREB-mediated transcription and calcium-channel activity, linking NPTX1 to calcium-dependent cell fate decisions.
In the Raji cell context, disruption of NPTX1 is predicted to desensitize cells to p53-mediated apoptosis, mimicking escape mechanisms observed in Burkitt lymphoma and other B-cell malignancies. This knockout model allows researchers to dissect the contribution of NPTX1 to p53-dependent cell death pathways independently of neuronal functions. Loss of NPTX1 may alter the BAX/BCL-2 rheostat, impair cytochrome c release, and reduce caspase-3 activation following DNA damage. Consequently, these cells are valuable for examining how tumor suppressor inactivation cooperates with EBV-driven proliferation, and for identifying synthetic vulnerabilities that arise from NPTX1 loss.
Researchers can employ the NPTX1 Knockout Raji Polyclonal Cells in a wide array of experimental workflows. Apoptosis induction assays with chemotherapeutics or DNA-damaging agents followed by Annexin V/propidium iodide flow cytometry and immunoblotting for cleaved caspase-3, BAX, and BCL-2 are highly informative. Transcriptional profiling via RT-qPCR can quantify p53 target genes and residual NPTX1 expression. Additional assays include calcium flux measurements, co-immunoprecipitation to probe residual protein interactions, and high-throughput screening for compounds that restore NPTX1 expression or bypass its loss. These cells also support investigation of tumor microenvironment interactions and combination therapy responses. For further technical details or custom requirements, please contact Ascent Research.
